Second Biosimilar Insulin OK'd; Diabetes Risk After COVID; Omnipod DASH Recall

The FDA approved the second interchangeable biosimilar insulin product, Eli Lilly's insulin glargine-aglr (Rezvoglar), for pediatric and adult patients with diabetes, the agency announced.

Patients with diabetes and chronic kidney disease should be considered for simultaneous pancreas-kidney transplantation independent of geography or location, said authors of a review on pancreas transplantation in the Journal of Clinical Endocrinology & Metabolism.

Should states be the ones to manufacture insulin? (Annals of Internal Medicine)

In a meta-analysis including almost 40 million people, there was an elevated risk for developing type 1 and type 2 diabetes across all ages and sexes following COVID-19 infection. (BMC Medicine)

The investigational pediatric growth hormone deficiency drug LUM-201 -- potentially the first oral medication for this condition -- induced a mean annualized height velocity of 8.6 cm at 6 months in a phase II trial, Lumos Pharma announced.

Adolescent girls living in areas of New York City with more violent crime tended to have a higher BMI, though this link wasn't seen in boys. (Health & Place)

The FDA announced a class I recall -- the most serious type -- for Insulet's Omnipod DASH Insulin Management System Personal Diabetes Manager for the risk of battery swelling, leakage, or extreme overheating.

We know that obesity isn't a simple condition, but what are all the possible causes? (New York Times)

Comment